Physician profile
Abbie Fulk
NPI 1598372328
$1,389.04
in general payments reported to CMS, 2019-2025
24 companies · $588 in 2025
The $588 reported for 2025 was more than what 76% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $158 · 2023: $226 · 2024: $417 · 2025: $588.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,231.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,231.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Specialty L.P. | $156.51 | 2023-2024 | Yupelri |
| Inspire Medical Systems, INC. | $133.65 | 2022 | |
| Abbvie INC. | $126.09 | 2023-2025 | |
| Travere Therapeutics, INC. | $119.29 | 2023-2025 | |
| Grifols USA, LLC | $113.11 | 2023-2025 | Prolastin-C Liquid |
| Astrazeneca Pharmaceuticals LP | $94.53 | 2023-2025 | Fasenra |
| Regeneron Healthcare Solutions, INC. | $91.61 | 2023-2025 | Dupixent |
| Takeda Pharmaceuticals U.S.A., INC. | $73.44 | 2023-2025 | Entyvio |
| Insmed, INC. | $72.99 | 2025 | Arikayce, Brinsupri |
| Pulmonx Corporation | $55.53 | 2025 | Chartis Catheter, Zephyr Delivery Catheter, Pulmonx Chartis Tablet Console |
| Phathom Pharmaceuticals, INC. | $48.08 | 2024 | Voquezna |
| Verona Pharma, INC. | $36.12 | 2025 | Ohtuvayre |
| Dexcom, INC. | $35.07 | 2024-2025 | Dexcom G6 Transmitter |
| Viatris Specialty LLC | $29.93 | 2025 | Yupelri |
| Novartis Pharmaceuticals Corporation | $27.13 | 2024 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $24.22 | 2025 | Acthar |
| Itamar Medical INC | $24.14 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $23.86 | 2024 | Rexulti |
| Calliditas Therapeutics US INC. | $21.54 | 2025 | Tarpeyo |
| Ceribell, INC. | $19.70 | 2025 | Pocket Eeg Device |
| Merck Sharp & Dohme LLC | $16.95 | 2024 | Vaxelis, Gardasil 9, Gardasil |
| Scpharmaceuticals INC. | $15.70 | 2025 | |
| Rigel Pharmaceuticals, INC. | $15.53 | 2025 | Gavreto, Rezlidhia, Tavalisse |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.32 | 2025 | Jascayd |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Abbie Fulk listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.